Plasma Therapy Global Market Report 2026

Plasma therapy is a treatment approach that replaces missing or insufficient proteins to support individuals in leading healthier and more productive lives. It delivers antibodies to patients undergoing therapy through blood plasma donated by individuals who have recovered from illness.

The main types of plasma therapy include pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). Pure Platelet-Rich Plasma (P-PRP), also known as leucocyte-poor PRP products, are activated formulations that do not contain leucocytes and feature a low-density fibrin network. The various applications encompass orthopedics, arthritis, chronic tendinitis, bone repair and regeneration, dermatology, androgenic alopecia, plastic surgery, dental procedures, cardiac muscle injury, and others, and are utilized across multiple settings such as hospitals and clinics, laboratories, and research institutes.

Tariffs have influenced the plasma therapy market by increasing costs of imported PRP/PRF kits, reagents, and medical devices used in therapy preparation. Segments like leukocyte-rich PRP and injectable PRF are most affected, with regions such as North America and Europe facing higher import duties. This has raised treatment costs and slowed adoption in hospital and clinic settings. On the positive side, tariffs have encouraged local manufacturing, innovation in plasma therapy delivery systems, and development of cost-effective alternatives.

The plasma therapy market research report is one of a series of new reports from The Business Research Company that provides plasma therapy market statistics, including plasma therapy industry global market size, regional shares, competitors with a plasma therapy market share, detailed plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the plasma therapy industry. This plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasma therapy market size has grown rapidly in recent years. It will grow from $0.61 billion in 2025 to $0.69 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited awareness about plasma therapy benefits, reliance on conventional treatments, growing orthopedic and sports medicine procedures, increasing hospital and clinic infrastructure, early adoption of prp in cosmetic procedures.

The plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of advanced prp and prf formulations, rising regenerative medicine research, expansion of plasma therapy applications in chronic and cardiac injuries, increasing adoption in dermatology and dental care, growth of clinical trials and research institutes. Major trends in the forecast period include growing adoption of platelet-rich plasma (prp) and platelet-rich fibrin (prf) therapies, expansion of regenerative medicine and orthopedic applications, increasing use in dermatology, hair restoration, and plastic surgery, rising demand for injectable and membrane-based fibrin products, integration of research and clinical trials for enhanced therapeutic outcomes.

The increasing incidence of osteoarthritis is expected to fuel the growth of the plasma therapy market during the forecast period. Platelet-rich plasma (PRP), a form of plasma therapy, is widely regarded as a safe and effective treatment option for osteoarthritis. PRP is a concentrated autologous blood product rich in growth factors that is injected into affected joints to relieve symptoms by reducing inflammation and slowing the progression of the disease. For example, in September 2023, according to the Journal of Elsevier, a Netherlands-based publishing company, global osteoarthritis cases are projected to rise significantly by 2050, with increases of 74.9% (ranging from 59.4% to 89.9%) for knee osteoarthritis, 48.6% (ranging from 35.9% to 67.1%) for hand osteoarthritis, 78.6% (ranging from 57.7% to 105.3%) for hip osteoarthritis, and 95.1% (ranging from 68.1% to 135.0%) for other types of osteoarthritis. Common treatment approaches for osteoarthritis include autologous chondrocyte implantation and scaffold implants. Consequently, the growing prevalence of osteoarthritis is anticipated to drive demand for plasma therapy.

Key companies operating in the plasma therapy market are launching innovative products, such as ESG-410, to address evolving clinical needs and expand available treatment options. ESG-410 is an electrosurgical generator designed to improve efficiency and performance in the treatment of non-muscle-invasive bladder cancer (NMIBC) and benign prostatic hyperplasia. For instance, in June 2023, Olympus Corporation, a Japan-based medical technology company, introduced the next-generation ESG-410 electrosurgical generator for the treatment of bladder cancer and enlarged prostate conditions. The ESG-410 incorporates advanced design features, including enhanced capacitors that ensure improved plasma stability during ignition. It offers rapid ignition and optimized plasma stability, delivering performance enhancements compared to the ESG-400, particularly when used with different loop sizes and oval buttons. The ESG-410 electrosurgical generator supports advanced treatment for NMIBC and BPH through a wide selection of resection loops, electrodes, and vaporization instruments.

In October 2025, Accord Plasma B.V., a Netherlands-based provider of plasma-derived therapies, acquired Prothya Biosolutions B.V. for an undisclosed amount. Through this acquisition, Accord Plasma B.V. aims to strengthen its global plasma therapy operations, improve production efficiency, expand access to high-quality plasma-derived products, and reinforce its position within the biopharmaceutical industry. Prothya Biosolutions B.V. is a US-based plasma collection and manufacturing company specializing in plasma-derived therapies.

Major companies operating in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex Inc., Biotest AG, China Biologic Products Holdings Inc., DePuy Synthes Companies, CSL Limited, Grifols S.A., Octapharma AG, Terumo BCT Inc., Pfizer Inc., Kedrion Biopharma, ADMA Biologics Inc., SK Plasma Co. Ltd., Kamada Ltd., Fusion HealthCare, LFB Plasma, Baxter International Inc., Bayer AG, GC Biopharma Corp, Hualan Biological Engineering Inc., Japan Blood Products Organization, PlasmaCare Inc., ProMetic Life Sciences Inc., Sanquin, Shanghai RAAS Blood Products Co. Ltd., Canadian Plasma Resources, B Positive Plasma, Proesis Biologics Inc.

North America was the largest region in the plasma therapy market in 2025. The Middle East is expected to be the fastest-growing region in the global plasma therapy market share during the forecast period. The regions covered in the plasma therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plasma therapy market includes revenues earned by entities by replacing missing or deficient proteins and developing better means of managing the disease. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plasma Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses plasma therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for plasma therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The plasma therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Pure PRP; Leukocyte-rich PRP; Pure Platelet-rich Fibrin (PRF); Leukocyte-rich Fibrin (L-PRF)
• 2) By Application: Orthopedics; Arthritis; Chronic Tendinitis; Bone Repair & Regeneration; Dermatology; Androgenic Alopecia; Plastic Surgery; Dental; Cardiac Muscle Injury; Other Applications
• 3) By End-Users: Hospitals & Clinics; Laboratories: Research Institutes
• Subsegments:
• 1) By Pure PRP: High Concentration PRP; Low Concentration PRP
• 2) By Leukocyte-Rich PRP: PRP With White Blood Cells; PRP With Growth Factors
• 3) By Pure Platelet-rich Fibrin (PRF): Injectable PRF; Membrane PRF
• 4) By Leukocyte-rich Fibrin (L-PRF): L-PRF Clots; L-PRF Membranes
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Bio Products Laboratory Ltd.; Arthrex Inc.; Biotest AG; China Biologic Products Holdings Inc.; DePuy Synthes Companies; CSL Limited; Grifols S.A.; Octapharma AG; Terumo BCT Inc.; Pfizer Inc.; Kedrion Biopharma; ADMA Biologics Inc.; SK Plasma Co. Ltd.; Kamada Ltd.; Fusion HealthCare; LFB Plasma; Baxter International Inc.; Bayer AG; GC Biopharma Corp; Hualan Biological Engineering Inc.; Japan Blood Products Organization; PlasmaCare Inc.; ProMetic Life Sciences Inc.; Sanquin; Shanghai RAAS Blood Products Co. Ltd.; Canadian Plasma Resources; B Positive Plasma; Proesis Biologics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.